Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2952 studies found for:    non-Hodgkin's lymphoma
Show Display Options
Rank Status Study
21 Completed Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Intervention: Drug: sorafenib tosylate
22 Withdrawn Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Vorinostat in combination with Bortezomib
23 Completed Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: Motexafin gadolinium
24 Completed
Has Results
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: Velcade;   Drug: Rituximab
25 Active, not recruiting A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma (GAUDI)
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone);   Drug: FC(fludarabine,cyclophosphamide);   Drug: RO5072759;   Drug: bendamustine
26 Terminated Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkins Lymphoma
Intervention: Drug: alemtuzumab
27 Completed Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era
Condition: Non-Hodgkin's Lymphoma
Intervention:
28 Terminated Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Standard CHOP;   Drug: Bi-CHOP (dose intensified CHOP)
29 Active, not recruiting An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: ABT-199
30 Unknown  Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine-131 Anti-B1 Antibody
31 Completed Treatment for Subjects With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: pegfilgrastim;   Drug: Filgrastim
32 Completed Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma
Conditions: Advanced Solid Tumor;   Lymphoma, Non-Hodgkin;   Non-Hodgkin's Lymphoma
Intervention: Drug: GSK461364
33 Active, not recruiting Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Non-Hodgkins Lymphoma
Interventions: Drug: Velcade;   Drug: Temsirolimus
34 Completed Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Tumors;   Non Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
35 Completed A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma
Interventions: Drug: SyB L-0501;   Drug: Rituximab
36 Terminated Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Advanced Solid Tumors;   Non-Hodgkin's Lymphoma
Intervention: Drug: RH-1
37 Completed Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: TRU-016 (anti-CD37 protein therapeutic)
38 Active, not recruiting A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: YM155;   Biological: Rituximab
39 Recruiting Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Bendamustine hydrochloride
40 Unknown  Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine-131 Anti-B1 Antibody

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years